936901-72-3

Basic information

• Product Name: 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone
• Synonyms: 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone;3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutan-1-one;3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone;3-(8-Chloroimidazo[1,5-A]Pyrazin-3-Yl)Cyclobutanone(WXC04773)
• CAS NO: 936901-72-3
• Molecular Formula: C10H8ClN3O
• Molecular Weight: 221.65
• EINECS: -0
• Mol File: 936901-72-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1 +-.0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.30±0.30(Predicted)
• CAS DataBase Reference: 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(936901-72-3)
• EPA Substance Registry System: 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone(936901-72-3)

Safety Data

• Hazardous Substances Data: 936901-72-3(Hazardous Substances Data)

Usage

General Description

3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is a chemical compound with the molecular formula C11H7ClN2O. It is a cyclobutanone derivative that contains a chloro-substituted pyrrolopyrazine group. 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is known for its potential pharmaceutical and medicinal applications, particularly in the field of drug discovery and development. The unique structure of 3-(1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone makes it a promising candidate for the design and synthesis of novel drugs targeting various biological pathways and disease conditions. Further research and studies are needed to explore the full potential and applications of this compound in the field of pharmaceutical science.

Upstream product

• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 939412-81-4 3-oxocyclobutanecarboxylic acid 2,5-dioxopyrrolidin-1-yl ester 
• 939412-84-7 N-[(2-chlorophenyl(methyl))]-3-oxocyclobutanecarboxamide 
• 939412-86-9 C-(3-chloropyrazin-2-yl)-methylamine hydrochloride salt 

Relevant articles and documents

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics

This letter describes a series of small molecule inhibitors of IGF-1R with unique time-dependent binding kinetics and slow off-rates. Structure-activity and structure-kinetic relationships were elucidated and guided further optimizations within the series

Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA?).